ABT-263对顺铂耐药食管癌细胞的抑制作用

Abstract
Figure/Table
References (20)
Related Citation (15)

Download: PDF (1098 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effect of ABT-263 on cisplatin-resistant esophageal cancer cell line of EC109/CDDP. Methods The cytotoxicity of ABT-263 in the cisplatin-resistant cell line EC109/CDDP and its parental cell line EC109 was measured by MTT assay. Colony formation assay was used to determine the effect of ABT-263 on cell renewable capacity of esophageal cancer cells. Flow cytometry was adopted to detect cell apoptosis. Western blot was used to investigate the changes of protein expression of PARP. Results MTT assay results showed that ABT-263 significantly inhibited the cell viability of EC109 and EC109/CDDP. Colony formation assay indicated that ABT-263 inhibited the cell renewable capacity of esophageal cancer cells (P ＜ 0.01). Flow cytometry analysis revealed that ABT-263 induced apoptosis of esophageal cancer cells (P ＜ 0.01). Western blot results showed that ABT-263 significantly increased the protein expression of cleavage PARP (P < 0.05 or P ＜ 0.01). Conclusion ABT-263 exhibits cytostatic and cytotoxic effects on cisplatin-resistant esophageal cancer cell line EC109/CDDP and its parental cell line EC109, while it induces apoptosis.

Key words： ABT-263 Esophageal cancer Cisplatin-resistant Apoptosis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIN Qinghuan1 DING Rong1 BI Tingting1 LIN Jian2 DENG Guihua1

Cite this article:

LIN Qinghuan1 DING Rong1 BI Tingting1 LIN Jian2 DENG Guihua1. Inhibitory effect of ABT-263 on cisplatin-resistant esophageal cancer cells[J]. 中国医药导报, 2019, 16(2): 12-16.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2019/V16/I2/12

[1] Siegel RL，Miller KD，Jemal A. Cancer statistics，2015 [J]. CA Cancer J Clin，2015，65（1）：5-29.
[2] Ferlay J，Soerjomataram I，Dikshit R，et al. Cancer incidence and mortality worldwide：Sources，methods and major patterns in GLOBOCAN 2012 [J]. Int J Cancer，2015， 136（5）：E359-E386.
[3] Jemal A，Bray F，Center MM，et al. Global cancer statistics [J]. CA Cancer J Clin，2011，61（2）：69-90.
[4] Dasari S，Tchounwou PB. Cisplatin in cancer therapy：molecular mechanisms of action [J]. Eur J Pharmacol，2014， 740：364-378.
[5] Yu L，Chen M，Li Z，et al. Celecoxib antagonizes the cytotoxicity of cisplatin in human esophageal squamous cell carcinoma cells by reducing intracellular cisplatin accumulation [J]. Mol Pharmacol，2011，79（3）：608-617.
[6] Vogler M. Targeting BCL2-Proteins for the Treatment of Solid Tumours [J]. Adv Med，2014，2014：943648.
[7] Tse C，Shoemaker AR，Adickes J，et al. ABT-263：a potent and orally bioavailable Bcl-2 family inhibitor [J]. Cancer Res，2008，68（9）：3421-3428.
[8] Wang C，Huang SB，Yang MC，et al. Combining paclitaxel with ABT-263 has a synergistic effect on paclitaxel resistant prostate cancer cells [J]. PLoS One，2015，10（3）：e120913.
[9] 余乐，陈明辉，古春萍，等.顺铂下调铜离子转运蛋白1诱导人食管鳞癌细胞EC109耐药[J].南方医科大学学报，2011，31（5）：801-804.
[10] Enzinger PC，Mayer RJ. Esophageal cancer [J]. N Engl J Med，2003，349（23）：2241-2252.
[11] Pennathur A，Gibson MK，Jobe BA，et al. Oesophageal carcinoma [J]. Lancet，2013，381（9864）：400-412.
[12] Sawyers C. Targeted cancer therapy [J]. Nature，2004， 432（7015）：294-297.
[13] Sugase T，Makino T，Yamasaki M，et al. Histological changes of superficial esophageal squamous cell carcinoma after preoperative chemotherapy [J]. Esophagus，2018. [Epub ahead of print]
[14] Chen Q，Song S，Wei S，et al. ABT-263 induces apoptosis and synergizes with chemotherapy by targeting stemness pathways in esophageal cancer [J]. Oncotarget，2015， 6（28）：25883-25896.
[15] Lin QH，Que FC，Gu CP，et al. ABT-263 induces G1/G0-phase arrest，apoptosis and autophagy in human esophageal cancer cells in vitro [J]. Acta Pharmacol Sin，2017，38（12）：1632-1641.
[16] 郗照勇，刘扬中.顺铂耐药的分子机制[J].中国科学：化学，2014，44（4）：410-422.
[17] Cheng CY，Liu JC，Wang JJ，et al. Autophagy inhibition increased the anti-tumor effect of cisplatin on drug-resistant esophageal cancer cells [J]. J Biol Regul Homeost Agents，2017，31（3）：645-652.
[18] Shi H，Mao Y，Ju Q，et al. C-terminal binding protein2 mediates cisplatin chemoresistance in esophageal cancer cells via the inhibition of apoptosis [J]. Int J Oncol，2018， 53（1）：167-176.
[19] Hou XF，Xu LP，Song HY，et al. ECRG2 enhances the anti-cancer effects of cisplatin in cisplatin-resistant esophageal cancer cells via upregulation of p53 and downregulation of PCNA [J]. World J Gastroenterol，2017，23（10）：1796-1803.
[20] Yokoyama T，Kohn EC，Brill E，et al. Apoptosis is augmented in high-grade serous ovarian cancer by the combined inhibition of Bcl-2/Bcl-xL and PARP [J]. Int J Oncol，2017. [Epub ahead of print]